Auburn University research links a single dose of CognatiQ to significant working memory improvement
FutureCeuticals has announced the publication of a new scientific article highlighting the cognitive performance benefits of its patented ingredient, CognatiQ.
The study, conducted at Auburn University and published in the journal Nutrients, demonstrates the positive effects of CognatiQ on cognitive performance in a large, diverse, and healthy group of participants.
This study is unique as it challenges the effectiveness of a cognitive performance ingredient in an at-home setting, designed to mimic real-life conditions, rather than the highly controlled laboratory environments typically used in such research.
The study reports that a single 200mg dose of CognatiQ significantly improved cognitive performance just one hour after ingestion.
This improvement was directly linked to ‘working memory,’ an essential aspect of memory that is crucial for reasoning, comprehension, and decision-making.
Cognitive performance improvements from a single dose ranged between 25 percent and 80 percent, with targeted benefits such as enhanced focus, accuracy, and concentration, while also alleviating mental fatigue.
“Working memory,” a well-known term for neurologists, has gained renewed attention, partly due to New York Times best-selling author Richard Restak, a neurologist.
Restak has emphasized the importance of working memory, describing it as “the most critical type of memory,” particularly as people age.
“We are pleased the world is finally beginning to realize what neurologists have known for a long time: working memory is among the most crucial parts of our brain function,” said J. Randal Wexler, head of FutureCeuticals' R&D Department.
Wexler further stated, “The findings reported in this most recent paper directly link a single dose of CognatiQ to very significant improvements in working memory. We believe these findings demonstrate that CognatiQ can provide large, noticeable changes in cognitive performance, quickly.”
